Atlas Trials

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Clinical trial NCT01013506 · WITHDRAWN

Trial details

NCT number
NCT01013506
Sponsor
Vanderbilt-Ingram Cancer Center
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2009-08-01
Primary completion
2009-12-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.